The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancerClaudia von Arx, Lucia Del Mastro, Pietro De Placido et al.|Cancer Treatment Reviews|2022Cited by 115
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative reviewAnnarita Peddio, Alberto Servetto, Erica Pietroluongo et al.|Critical Reviews in Oncology/Hematology|2024Cited by 25
Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic InterventionRoberto Buonaiuto, Carmine De Angelis, Pietro De Placido et al.|Biomolecules|2023Cited by 14
Extraskeletal Ewing’s sarcoma of the mediastinum: Case reportAldo Caltavituro, Mario Giuliano, Roberto Buonaiuto et al.|Frontiers in Oncology|2023Cited by 9
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation typeRoberto Buonaiuto, Carmine De Angelis, Giuseppe Neola et al.|Frontiers in Oncology|2024Cited by 9